ESTRO 2024 - Abstract Book

S1625

Clinical - Lung

ESTRO 2024

The dashed lines are showing the 95% confidence interval

No grade 4-5 toxicities possibly related to treatment were registered. Eight acute grade 3 toxicities were registered, which caused discontinuation of treatment in three patients. Overall, grade 3 toxicities occurred in 12 patients (20%), the most common was pneumonitis (12%).

Conclusion:

This prospective study showed that high-dose reirradiation of in-field or marginal in-field recurrences in the thorax is feasible and achieved a high median OS of 30.1 months. It resulted also in good LC and DFS. The toxicity rates were acceptable, with no grade 4-5 treatment-related toxicities and only 12% of grade 3 pneumonitis.

Keywords: Re-irradiation, lung cancer, survival

779

Mini-Oral

Risk of left ventricular dysfunction after thoracic irradiation

Umut Fidan 1 , Arno C. Hessels 1 , Robin Wijsman 1 , Emmy Slager 1 , Jan Bussink 2 , Anthonie L. Duijnhouwer 3 , Tineke P. Willems 4 , Elke S. Hoendermis 5 , Johannes A. Langendijk 1 , Christina T. Muijs 1 , Peter van Luijk 1 1 University Medical Center Groningen, Radiation Oncology, Groningen, Netherlands. 2 Radboud University Medical Center, Radiation Oncology, Nijmegen, Netherlands. 3 Radboud University Medical Center, Cardiology, Nijmegen,